Full Scientific Program

Program Sorter

MASLD & Real life practice

Chairpersons - Hemamala Ilango, J R Mohapatra, Pankaj Singh, Shoket Chowdry, Uday Sanglodkar

🗓️ 21 Nov 2025 🕒 14:15 - 14:55 📍Hall B

Theme - PPAR agonists & SGLT2 Inhibitors: A Game Changer?
Educational Partner - Zydus

Objectives -

1. To analyze the role of SGLT2i role in management of diabetes in non morbidly obese patients.
2. To understand if PPARs still have any role in management of MASH?

Debate: SGLT2i are the anti-diabetic medications of choice for MASLD without morbid obesity

For

14:15 - 14:23 Debate

Speaker: Ameet Mandot

Debate: SGLT2i are the anti-diabetic medications of choice for MASLD without morbid obesity

Against

14:23 - 14:31 Debate

Speaker: Ashish Goel

Debate: SGLT2i are the anti-diabetic medications of choice for MASLD without morbid obesity

Rebuttal & Discussion

14:31 - 14:35 Debate

PPAR agonists in MASLD – Does it still have a role in GLP1 analouge era?

14:35 - 14:45 DidacticTalk

Speaker: Ajay Duseja

Moderated Q&A

14:45 - 14:55

Add to Favourite

MASLD Emerging Therapies & Challenges

Chairpersons - Golamari Srinivasa Reddy, M P Sharma, Muzaffer Rashid Shawl

🗓️ 21 Nov 2025 🕒 14:55 - 15:30 📍Hall B

Theme - Unlocking MASH's Future: The Promise of THR-beta Agonists
Educational Partner - Hetero Pharma

Objectives -

MASLD Emerging Therapies & Challenges

Add to Favourite

MASLD & Obesity

Chairpersons - Ajay Bhalla, Jayshree Sood, Kunal Das, Sunita Gupta

🗓️ 23 Nov 2025 🕒 9:00 - 9:50 📍Hall B

Theme - Obese MASLD: Are newer anti-obesity medications good enough?
Educational Partner- Novo Nordisk

Objectives -

1. To learn about newer medical anti-obesity strategies.
2. To learn about pre op optimization of obese cirrhotic with real world case.
3. To learn about strategies to reduce weight in cirrhosis before surgery.

Crossroads of Care - The intersection of Obesity and Liver Disease

9:00 - 9:08 Didactic Talk

Speaker: Ashish Kumar

Case-Based Panel Discussion: 45 yr Female with Decompensated CLD (CTP B7) with BMI 33 planned for right hemicolectomy for Carcinoma Colon. Pre op optimization strategy.

Sub Topics:

1. What are Challenges in this patient?

2. Cardiopulmonary assessment and optimization

3. Optimization of cirrhosis (Albumin infusion? TEG analysis, protein intake, variceal evaluation/ evaluation of portal hypertension/ collaterals)

4. Does pre op weight reduction in this patient will improves outcome/ strategies

5. Role of Bariatric Surgery

9:08 - 9:33 Case-Based Panel Discussion

Moderator : Narena Choudhary

Panelists: Amit Gupte, Biju Pottakkat, Mukul Rastogi, Randeep Wadhawan, Manisha Dwivedi

Managing Obesity in MASLD Candidates: GLP-1RA versus Surgical Approaches for Pre-Transplant Optimization

9:33 - 9:43 Didactic Talk

Speaker: Nazia Selzner

9:43 - 9:50 Moderated Q&A

Add to Favourite

MASLD and Liver Transplant

Chairpersons - Ashwini Chopra, Kishore G S B, Rohan Jagat Chaudhary, Surbhi, Tarun Kumar

🗓️ 23 Nov 2025 🕒 11:45 - 12:22 📍Hall A

Theme - Navigating the Metabolic Maze: MASLD and Liver Transplant Outcomes

Objectives -

1. To understand how Metabolic mayhem fuels the MASLD fire
2. To gain insights in optimizing MASLD donor
3. To understand pre op assessment & optimization of morbidly obese cirrhotic undergoing Liver Transplantation with case based panel discussion

Optimising donor with MASLD for Donation

11:45 - 11:53 Didactic Talk

Speaker: Gaurav Chaubal

Case based Panel Discussion: 58 yr old morbidly obese cirrhotic (MELD 20) planned for Liver Transplantation. Risk assessment and optimizing for Liver Transplantation

Sub-topics:

1. Morbid obesity and potential donor-recipient mismatch, in living donor LT (LDLT)?

2. What are the potential perioperative and post-transplant complications associated with obesity in this specific case?

3. Does the presence of sarcopenia (muscle wasting), along with obesity (sarcopenic obesity), further impact prognosis and potential post-LT complications?

4. What are the most appropriate and effective weight loss strategies for this patient, considering the liver function and potential risks of worsening malnutrition or sarcopenia? Does GLP1 agonist have any role?

5. If considering bariatric surgery, what are the optimal timing (before, during, or after LT) and the most appropriate surgical approach (e.g., sleeve gastrectomy), weighing the benefits and risks in this specific clinical context?

11:53 - 12:18 Panel Discussion

Moderator : Sharat Putta

Panelists: Ashish Malik, Prajna Anirvan, Punit Singla, Rajnish Monga, Naimish Mehta

Moderated Q&A

12:18 - 12:22

Add to Favourite